The National Quality Forum has endorsed 14 neurology quality measures and 10 behavioral health quality measures.
The neurology measures are specifically focused on stroke treatment and rehabilitation, while the behavioral health quality measure focus on issues such as alcohol and tobacco abuse, antipsychotic medication adherence and follow-up care after hospitalization for mental illness.
Endorsed measures include:
Neurology
• 0240: Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage (AMA-PCPI)
• 0241: Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge (AMA-PCPI)
• 0243: Stroke and Stroke Rehabilitation: Screening for Dysphagia (AMA-PCPI)
• 0244: Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered (AMA-PCPI)
• 0325: Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy (AMA-PCPI)
• 0434: STK-01: Venous Thromboembolism (VTE) Prophylaxis (The Joint Commission)
• 0435: STK 02: Discharged on Antithrombotic Therapy (The Joint Commission)
• 0436: STK-03: Anticoagulation Therapy for Atrial Fibrillation/Flutter (The Joint Commission)
• 0437: STK 04: Thrombolytic Therapy (The Joint Commission)
• 0438: STK 05: Antithrombotic Therapy By End of Hospital Day Two (The Joint Commission)
• 0439: STK-06: Discharged on Statin Medication (The Joint Commission)
• 0441: STK-10: Assessed for Rehabilitation (The Joint Commission)
• 0467: Acute Stroke Mortality Rate (IQI 17) (AHRQ)
• 1952: Time to Intravenous Thrombolytic Therapy (AHA/ASA)
Behavioral health
• 0004: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (NCQA)
• 0027: Medical Assistance With Smoking and Tobacco Use Cessation (NCQA)
• 0028: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention (AMA-PCPI)
• 1879: Adherence to Antipsychotic Medications for Individuals with Schizophrenia (CMS)
• 1932: Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (SSD) (NCQA)
• 1927: Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (NCQA)
• 1933: Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia (SMC) (NCQA)
• 1934: Diabetes monitoring for people with diabetes and schizophrenia (NCQA)
• 1937: Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA)
• 0576: Follow-Up After Hospitalization for Mental Illness (NCQA)
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
The neurology measures are specifically focused on stroke treatment and rehabilitation, while the behavioral health quality measure focus on issues such as alcohol and tobacco abuse, antipsychotic medication adherence and follow-up care after hospitalization for mental illness.
Endorsed measures include:
Neurology
• 0240: Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage (AMA-PCPI)
• 0241: Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge (AMA-PCPI)
• 0243: Stroke and Stroke Rehabilitation: Screening for Dysphagia (AMA-PCPI)
• 0244: Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered (AMA-PCPI)
• 0325: Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy (AMA-PCPI)
• 0434: STK-01: Venous Thromboembolism (VTE) Prophylaxis (The Joint Commission)
• 0435: STK 02: Discharged on Antithrombotic Therapy (The Joint Commission)
• 0436: STK-03: Anticoagulation Therapy for Atrial Fibrillation/Flutter (The Joint Commission)
• 0437: STK 04: Thrombolytic Therapy (The Joint Commission)
• 0438: STK 05: Antithrombotic Therapy By End of Hospital Day Two (The Joint Commission)
• 0439: STK-06: Discharged on Statin Medication (The Joint Commission)
• 0441: STK-10: Assessed for Rehabilitation (The Joint Commission)
• 0467: Acute Stroke Mortality Rate (IQI 17) (AHRQ)
• 1952: Time to Intravenous Thrombolytic Therapy (AHA/ASA)
Behavioral health
• 0004: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (NCQA)
• 0027: Medical Assistance With Smoking and Tobacco Use Cessation (NCQA)
• 0028: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention (AMA-PCPI)
• 1879: Adherence to Antipsychotic Medications for Individuals with Schizophrenia (CMS)
• 1932: Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (SSD) (NCQA)
• 1927: Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (NCQA)
• 1933: Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia (SMC) (NCQA)
• 1934: Diabetes monitoring for people with diabetes and schizophrenia (NCQA)
• 1937: Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA)
• 0576: Follow-Up After Hospitalization for Mental Illness (NCQA)
More Articles on NQF:
NQF Endorses Patient Safety, Cancer Care and Other Measures
NQF Upholds Endorsement of All-Cause Readmissions Measure
NQF Endorses Complications-Related Patient Safety Measures
